Circulating miR-215-5p and miR-642a-5p as potential biomarker for diagnosis of osteosarcoma in Mexican population

Monterde-Cruz, Lucero; Ramírez‐Salazar, Eric G.; Rico-Martínez, Genaro; Linares-González, Luis Miguel; Guzmán-González, Roberto; Delgado-Cedillo, Ernesto Andrés; Estrada-Villaseñor, Eréndira; Valdés-Flores, Margarita; Velázquez‐Cruz, Rafael; Hidalgo‐Bravo, Alberto

doi:10.1007/s13577-018-0214-1

Cited by 33 publications

(24 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MiR-let-7a, quantified in total blood of osteosarcoma patients, is considered a potential diagnostic (AUC = 0.90) and negative prognostic biomarker for osteosarcoma [281]. In a small Mexican cohort, microarray analysis of 648 serum miRNAs revealed that only miR-642a-5p and miR-215-5p are upregulated in osteosarcoma, with AUC of 0.84 and 0.87 [282].…”

Section: Mirnas As Tumor Biomarkersmentioning

confidence: 99%

Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma

Bottani

Banfi

Lombardi

2019

JCM

View full text Add to dashboard Cite

An early cancer diagnosis is essential to treat and manage patients, but it is difficult to achieve this goal due to the still too low specificity and sensitivity of classical methods (imaging, actual biomarkers), together with the high invasiveness of tissue biopsies. The discovery of novel, reliable, and easily collectable cancer markers is a topic of interest, with human biofluids, especially blood, as important sources of minimal invasive biomarkers such as circulating microRNAs (miRNAs), the most promising. MiRNAs are small non-coding RNAs and known epigenetic modulators of gene expression, with specific roles in cancer development/progression, which are next to be implemented in the clinical routine as biomarkers for early diagnosis and the efficient monitoring of tumor progression and treatment response. Unfortunately, several issues regarding their validation process are still to be resolved. In this review, updated findings specifically focused on the clinical relevance of circulating miRNAs as prognostic and diagnostic biomarkers for the most prevalent cancer types (breast, lung, and prostate cancers in adults, and osteosarcoma in children) are described. In addition, deep analysis of pre-analytical, analytical, and post-analytical issues still affecting the circulation of miRNAs’ validation process and routine implementation is included.

show abstract

Section: Mirnas As Tumor Biomarkersmentioning

confidence: 99%

Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma

Bottani

Banfi

Lombardi

2019

JCM

View full text Add to dashboard Cite

show abstract

“…The highly dysregulated miR-25-3p correlates with patient prognosis, and might serve as a non-invasive blood-based biomarker for tumor monitoring and prognostic prediction. Correlation between miR-25 expression and bone metabolism was reported previously, with intracellular and extracellular oncogenic functions imputed to miR-25-3p [32,[54][55][56]. Another study conducted a meta-analysis to assess the true diagnostic value of circulating miRNAs for early detection of OS [57].…”

Section: Discussionmentioning

confidence: 77%

“…In addition, TaqMan Low Density Arrays identified 15 miRNAs that are differentially expressed in OS patients compared with healthy controls; of these, miR-215-5p and miR-642a-5p are potential markers for OS diagnosis [32]. Genome-wide profiling identified 56 and 164 c-miRNAs that were upregulated and downregulated, respectively, in OS samples.…”

Section: Discussionmentioning

confidence: 99%

Signatures of circulating microRNA in four sarcoma subtypes

Koseła-Paterczyk¹,

Paziewska²,

Kulecka³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: Sarcomas are rare malignant tumors of mesenchymal origin. The discovery of circulating biomarkers with high diagnostic value could supplement diagnosis of this heterogenous group of tumors. The aim of this study was to identify the profiles of circulating miRNA (c-miRNAs) in four groups of common bone and soft tissue sarcomas. Methods: At the time of diagnosis, blood samples were collected from 86 patients: 36 with locally advanced/unresectable/metastatic gastrointestinal stromal tumor (GIST) who received first-line treatment with imatinib; 16 with locally advanced osteosarcoma (OS); 26 with locally advanced synovial sarcoma (SS); and eight with locally advanced Ewing sarcoma (ES). In addition, samples were collected from 30 healthy controls. C-miRNAs were isolated using a miRCURY RNA Isolation Kit, followed by preparation of cDNA libraries and sequencing on the Ion Proton platform. Results: Pair-wise comparisons identified 156 unique c-miRNAs (adjusted P-value < 0.05) showing significant dysregulation between controls and patients; of these, 24, 36, 42, and 99 differentiated controls from pretherapeutic OS, SS, ES, and GIST, respectively. Ten c-miRNAs were commonly altered in at least three sarcoma types. Receiver operating characteristic curves and area under the curve (ROC-AUC) analyses revealed that a four-miRNA diagnostic classifier was able to differentiate controls from ES, GIST, OS, and SS, with AUC-ROC values of 1, 0.97, 0.95, and 0.94, respectively. Conclusions: Aberrant miRNA expression signatures were identified in serum from patients with four different sarcoma subtypes. Differences in miRNA expression profiles between sarcoma patients and healthy volunteers suggest that miRNAs may play a role in sarcoma development.

show abstract

“…miR-26a suppresses osteosarcoma metastasis by targeting HMGA1 [18]. MiR-215-5p and miR-642a-5p may be potential biomarkers for diagnosis of osteosarcoma [19]. And miR-660 promotes osteosarcoma cell proliferation and invasion [20].…”

Section: Discussionmentioning

confidence: 99%

miR-627-3p inhibits osteosarcoma cell proliferation and metastasis by targeting PTN

Shen

Qiu

et al. 2019

Aging

View full text Add to dashboard Cite

Dysregulation of microRNA (miRNA) has been observed in several types of tumors, including osteosarcoma. Biochip analysis was used to identify miRNAs differentially expressed in osteosarcoma tissues. The targeting sites of miR-627-3p were analyzed using miRDB software and fluorescein reporter gene. MTT and Transwell assays were used to analyze the effects of miR-627-3p on the growth and migration of osteosarcoma cells. Western blotting and real-time PCR were used to detect the effects of miR-627-3p on related proteins. In vivo experiments were conducted to verify the effect of miR-627-3p on osteosarcoma. We focused on miR-627-3p because it was the most significantly downregulated miRNA in our screening study. Through luciferase reporter assays, western blotting and real-time PCR we found that miR-627-3p directly targets PTN, and that expression levels of miR-627-3p and PTN are negatively correlated in osteosarcoma cells. Downregulation of miR-627-3p promoted osteosarcoma cell proliferation and metastasis, while its overexpression had the opposite effect. By targeting PTN, miR-627-3p also suppressed expression of Cyclin D1 and MMP2. MiR-627-3p inhibited osteosarcoma metastasis in vivo. Thus, miR-627-3p may be a useful therapeutic target for the treatment osteosarcoma or prevention of metastasis.

show abstract

Circulating miR-215-5p and miR-642a-5p as potential biomarker for diagnosis of osteosarcoma in Mexican population

Cited by 33 publications

References 25 publications

Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma

Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma

Signatures of circulating microRNA in four sarcoma subtypes

miR-627-3p inhibits osteosarcoma cell proliferation and metastasis by targeting PTN

Contact Info

Product

Resources

About